Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that Genentech/Novartis/Sankyo/Tanox Biosystems' Xolair will lead the growth of the asthma market with major-market sales of $3.3 billion in 2012. According to the new Pharmacor study entitled Asthma, Xolair is poised to address the needs of patients with severe, refractory, allergic asthma that remain symptomatic despite pharmacological intervention. However, uptake of Xolair will be limited by its high cost and inconvenient route of administration (intravenous injection).

"Physicians interviewed claim that severe, refractory asthmatics are often administered high doses of oral or injectable corticosteroids that may lead to dependence and several serious side effects, such as osteoporosis and formation of cataracts," said Stephen Ames, analyst at Decision Resources. "They state that Xolair will enable such patients to lower their corticosteroid doses to more manageable levels."

About Asthma

As a chronic inflammatory disorder, asthma causes significant morbidity in affected individuals, including permanent structural damage to the airways and long-term reductions in lung function. Although many asthmatics respond well to currently available treatments, significant unmet needs remain.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (www.decisionresources.com) is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Boehringer Ingelheim/Pfizer's Spiriva will Corner the COPD Drug Market with 45% Share in 2012

View Now